The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending dostarlimab as monotherapy in women with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
